# Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

Study · id `cardio:ct-nct03596450` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03596450](<https://clinicaltrials.gov/study/NCT03596450>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03596450

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1278 participants.

## Technical summary

Registry record NCT03596450. Randomized; no masking; primary purpose treatment. Start 2018-07-13 (actual); primary completion 2022-06-09 (actual). Results posted on 2023-08-15.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1278 participants (enrolled count; ClinicalTrials.gov record NCT03596450, source copy `cardio:ctgov-nct03596450-2026-09-30`, retrieved 2026-10-26)
- Started: 2018-07-13 (actual) (ClinicalTrials.gov record NCT03596450, source copy `cardio:ctgov-nct03596450-2026-09-30`, retrieved 2026-10-26)
- Primary completion: 2022-06-09 (actual) (ClinicalTrials.gov record NCT03596450, source copy `cardio:ctgov-nct03596450-2026-09-30`, retrieved 2026-10-26)
- Completion: 2023-06-09 (actual) (ClinicalTrials.gov record NCT03596450, source copy `cardio:ctgov-nct03596450-2026-09-30`, retrieved 2026-10-26)
- Results first posted: 2023-08-15 (ClinicalTrials.gov record NCT03596450, source copy `cardio:ctgov-nct03596450-2026-09-30`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT03596450, source copy `cardio:ctgov-nct03596450-2026-09-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03596450-2026-09-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Semaglutide
- Intervention (Drug): Standard of care
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 72bc57aece213cc9e87130da6f8b0a6552bd2b057e70559be4d993b3e2ad706b
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
